Overview

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

Status:
Completed

Trial end date:
2017-04-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine administered on a 0- and 1- to 2-months schedule in adults 18 years of age or older who are receiving chronic immunosuppressive therapy.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines